Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck

Sandeep Samant, Michiel W. Van Den Brekel, Merrill S. Kies, Jim Wan, K. Thomas Robbins, David I. Rosenthal, Coen Rasch, Randal S. Weber

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Background We performed a retrospective review of patients with nonresected head and neck adenoid cystic carcinoma (ACC) treated with concurrent chemoradiation. Methods Sixteen patients (nasopharynx 7, oropharynx 4, trachea 3, oral and nasal cavity 1 each) were treated at 3 tertiary care centers. Six patients received intraarterial cisplatin and 10 received intravenous cisplatin or carboplatin concurrently with radiation. Results Thirteen patients are alive, 7 without signs of disease with a median follow-up of 61 months. Tumor progression was noted in 8 patients (50%) (distant metastasis in 5 patients and local tumor progression in 3 patients) with a median time to progression of 25 months (range, 4-52 months). Overall survival (OS), progression-free survival (PFS), and local progression-free survival (LPFS) rates at 5 years were 87%, 39%, and 61%, respectively. Conclusion Concurrent chemoradiation is a feasible treatment option and may lead to sustained locoregional tumor control in patients with nonresected ACC of the head and neck.

Original languageEnglish
Pages (from-to)1263-1268
Number of pages6
JournalHead and Neck
Volume34
Issue number9
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Dive into the research topics of 'Concurrent chemoradiation for adenoid cystic carcinoma of the head and neck'. Together they form a unique fingerprint.

Cite this